ReviewChest2023
Optimizing Vasopressin Use and Initiation Timing in Septic Shock: A Narrative Review.
Review in Chest, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07453901 (The Multicentre Prospective Observational Study on the Management of Septic Shock), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Multicentre Prospective Observational Study on the Management of Septic Shock (Observational Study on Septic Shock, the OSS Study)
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Efficacy of targeting high mean arterial pressure for older patients with septic shock (OPTPRESS): a multicentre, pragmatic, open-label, randomised controlled trial.Intensive care medicine · 2025Trial
- Efficacy of milrinone combined with norepinephrine in improving hemodynamics and protecting liver/kidney function in patients with septic shock.Pakistan journal of medical sciences · 2026Article
- Maternal Corporeal Support in Terminal Stage Brain Astrocytoma: A Case Report and Literature Review.Healthcare (Basel, Switzerland) · 2026Article
- Modulation of the Vasopressin System in Distributive and Cardiogenic Shock: Theoretical Principles and Practical Applications.Journal of clinical medicine · 2026Review
- Effects of Dobutamine and Vasopressin on Microcirculation and Mitochondrial Function in the Liver and Colon of Septic Rats: A Randomized Placebo-Controlled Trial.Shock (Augusta, Ga.) · 2026Article
- Severity-stratified vasopressor-escalation strategies in septic shock: a cross-fitted doubly robust analysis with external replication.Frontiers in pharmacology · 2026Article
- Development and validation of a nomogram for early prediction of sepsis-associated liver injury: a multicenter study.Frontiers in medicine · 2026Article
- Interpretable machine learning models for predicting New-onset acute organ injury within 48 hours of admission in patients with community-acquired acute cholangitis.Frontiers in medicine · 2026Article
- ABC'S of AI: proposing a clinician's framework for the interpretation of artificial intelligence studies.Frontiers in medicine · 2026Article
- Prognostic discrimination of SOFA-2 vs. SOFA-1 and incremental information from cardiovascular scoring and vasoactive support intensity in patients with sepsis receiving early vasoactive therapy.Frontiers in cardiovascular medicine · 2026Article
- Vasopressin Initiation Timing and In-Hospital Mortality in Septic Shock: An Observational Study of Large Public Databases.Critical care explorations · 2025Observational
- Vasopressin and its analogues in patients with septic shock: holy Grail or unfulfilled promise?Critical care (London, England) · 2025Review
- Predicting responsiveness to fixed-dose methylene blue in adult patients with septic shock using interpretable machine learning: a retrospective study.Scientific reports · 2025Article
- A Mortality Risk Prediction Model for Septic Shock in Patients Aged ≥50: Role of Norepinephrine Index and Procalcitonin.International journal of general medicine · 2025Article
- Machine learning approach for the prediction of 30-day mortality in patients with sepsis-associated delirium.PloS one · 2025Article
- Timing of adjunctive vasopressin initiation for septic shock patients and hospital mortality: A multicentre observational study.Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
topic importanceThis review discusses the rationale for vasopressin use, summarizes the results of clinical trials evaluating vasopressin, and focuses on the timing of vasopressin initiation to provide clinicians guidance for optimal adjunctive vasopressin initiation in patients with septic shock. REVIEW
findingsPatients with septic shock require vasoactive agents to restore adequate tissue perfusion. After norepinephrine, vasopressin is the suggested second-line adjunctive agent in patients with persistent inadequate mean arterial pressure. Vasopressin use in practice is heterogeneous likely because of inconsistent clinical trial findings, the lack of specific recommendations for when it should be used, and the high drug acquisition cost. Despite these limitations, vasopressin has demonstrated price inelastic demand, and its use in the United States has continued to increase. However, questions remain regarding optimal vasopressin use in patients with septic shock, particularly regarding patient selection and the timing of vasopressin initiation. SUMMARY: Experimental studies evaluating the initiation timing of vasopressin in patients with septic shock are limited, and recent observational studies have revealed an association between vasopressin initiation at lower norepinephrine-equivalent doses or lower lactate concentrations and lower mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.